|
Prosonix Announce Agreement With Trimel Biopharma |
 |
 |
 |
|
Written by Graham Ruecroft
|
|
Tuesday, 13 July 2010 00:00 |
|
|
|
Last Updated on Tuesday, 13 July 2010 11:43 |
|
|
Prosonix Announce The Scale-Up Of UMAX technology |
|
|
|
|
Written by Graham Ruecroft
|
|
Sunday, 04 April 2010 00:00 |
 In just a short space of time since its launch Prosonix has successfully scaled up of the UMAX ® particle engineering technology. The scale-up has now been carried out on several APIs in cGMP facilities and importantly demonstrates a seamless transition from laboratory to commercial scale batches, with no loss of formulation performance, independent of delivery platform or device.
|
|
Last Updated on Sunday, 04 April 2010 16:18 |
|
Prosonix CEO David Hipkiss talks to in-Pharma |
|
|
|
|
Written by Graham Ruecroft
|
|
Wednesday, 17 March 2010 00:00 |
|
|
|
Last Updated on Wednesday, 07 April 2010 17:19 |
|
|
Prosonix CEO David Hipkiss talks to CHEManager |
|
|
|
|
Written by Graham Ruecroft
|
|
Wednesday, 24 February 2010 00:00 |
 David Hipkiss, CEO of Prosonix, recently spoke to CHEM-anager Europe about the company's endeavours in using its proprietary sonocrystallization and particle engineering technologies for Making Better Medicines. Within this discussion David spoke at length about the application of proprietary pharmaceutical ultrasonic particle engineering technologies, ultrasonic process chemistry and processing equipment to deliver sustainable value to the pharmaceutical industry.
|
|
Last Updated on Wednesday, 07 April 2010 13:39 |
|
Prosonix Wins Award at Major Conference- DDL-20 |
|
|
|
|
Written by Graham Ruecroft
|
|
Sunday, 13 December 2009 00:00 |
Prosonix was delighted to win the best industrial poster award at Europe's premier conference and exhibition dedicated to pulmonary and nasal drug delivery, namely Drug Delivery to the Lungs - DDL20, which took place from Wednesday 9th - Friday 11th December 2009, in its 20th year!
|
|
Last Updated on Thursday, 18 March 2010 11:13 |
|
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 Next > End >>
|
|
Page 1 of 9 |
Prosonix has announced that it has entered into a multi-product co-development and licensing agreement with Trimel Biopharma (a subsidiary of Trimel Biopharma Holdings -Barbados) in order to collaborate in combining Prosonix' particle engineering technology and leadership with Trimel's award winning unit dose, single use, disposable dry powder inhaler technology. For further details please see the following and refer to the attached press release:
David Hipkiss, CEO of Prosonix, recently spoke to in-Pharma technologist.com about the company's recent launch of its new 